What Are Long-Term Complications of Primary Immunodeficiency
At a Glance
Routine monitoring is important in primary immunodeficiency because lung inflammation, immune attacks on blood cells, and lymph-node or cancer-related changes may develop before symptoms. The right tests and schedule depend on the specific diagnosis, age, genetics, and medical history.
In this answer
5 sections
Many people with a primary immunodeficiency (PID) or inborn error of immunity (IEI) wonder why they need regular lung scans, blood tests, and specialist visits when they aren’t feeling sick. The short answer is that PID is a large, diverse group of genetic disorders, and some types affect how your immune system regulates itself, not just how well it fights infection [1].
Because of this immune dysregulation, some patients are at risk for non-infectious complications—such as lung inflammation, autoimmune issues, and abnormal cell growth—that can begin developing before noticeable symptoms appear [1][2]. Routine screening can help your care team detect abnormalities early. However, it is important to remember that your surveillance plan is highly individualized. Your exact diagnosis, age, genetics, and medical history determine which tests you need and how often. Routine monitoring is a proactive tool; it does not mean you are expected to develop every complication discussed here.
Monitoring for Non-Infectious Lung Disease
One reason for regular pulmonary (lung) evaluation is to monitor for non-infectious complications. For example, people with Common Variable Immunodeficiency (CVID) are at risk for Granulomatous-Lymphocytic Interstitial Lung Disease (GLILD), a condition where immune cells clump together and cause inflammation in the lungs [3][4]. GLILD affects roughly 10% to 30% of people with CVID [3].
GLILD can be clinically subtle, meaning it can cause structural changes in the lungs even if you do not have a cough or shortness of breath [5]. Because standard breathing tests can sometimes remain stable while lung inflammation progresses, international clinical practice guidelines recommend screening adults with CVID for GLILD using a combination of tests [6][7]:
- High-Resolution CT (HRCT): A detailed imaging scan of the lungs.
- Pulmonary Function Tests (PFTs): Breathing tests that measure lung capacity and often include a “gas-transfer” assessment (measuring how well oxygen moves from your lungs into your blood).
Note on CT Scans: While guidelines recommend a baseline HRCT for adults with CVID, this does not mean everyone needs a CT scan every year. Because CT scans involve radiation exposure, your doctor will tailor your ongoing imaging schedule based on your baseline results, breathing tests, and specific disease risks [8][9].
Autoimmune Blood Disorders
In a healthy system, immune cells know not to attack the body’s own tissues. In some forms of PID, this regulation fails, leading to autoimmunity [1]. A common complication is autoimmune cytopenia, where the immune system attacks blood cells [10]. This can manifest as:
- Immune thrombocytopenia (ITP): Destruction of platelets, which help blood clot.
- Autoimmune hemolytic anemia (AIHA): Destruction of red blood cells, which carry oxygen.
A systematic medical review found that these conditions affect roughly 10% of people with CVID, and in some specific genetic disorders, they can be the very first sign of an immune problem [10][11]. Regular Complete Blood Counts (CBC) during your specialist visits help monitor for these issues early, often before you feel unusual fatigue or notice bruising [12].
Lymph Node Changes and Cancer Risk
Another focus of long-term surveillance is lymphoproliferation—the abnormal or excessive accumulation of immune cells, leading to enlarged lymph nodes, an enlarged spleen, or an enlarged liver [13]. Enlarged lymph nodes can reflect a benign reactive inflammation, an infection, an autoimmune response, or, less commonly, a malignancy (cancer) [13][14].
People with certain primary immunodeficiencies have a higher risk of developing malignancies, particularly blood cancers like lymphoma and leukemia [15][16]. The risk varies substantially depending on your exact genetic diagnosis, age, and history with viral infections [17]. For context, in one specific registry of patients with CVID in Spain, about 15% developed cancer over time, most frequently lymphoma [15]. This statistic represents that specific studied group and is not a universal prediction for everyone with an immune deficiency. Routine check-ups allow your doctor to evaluate any persistent node enlargement to distinguish between benign and malignant processes [18].
When to Contact Your Doctor Between Visits
While routine visits are for long-term monitoring, do not wait for your next scheduled appointment if you develop new or concerning symptoms. Contact your care team promptly if you experience:
- Rapidly worsening shortness of breath or severe chest symptoms
- Coughing up blood
- Unusual, unexplained, or persistent bleeding (including widespread pinpoint bruising, bloody stools, or dark urine)
- Marked weakness, fainting, severe pallor (paleness), or jaundice (yellowing of skin/eyes)
- Rapidly enlarging, hard, or fixed lymph nodes
- Unexplained drenching night sweats or persistent fever (always follow your personal infection action plan)
Empowering Your Care
Your specialist appointments—which may include symptom reviews, physical exams of your lymph nodes and spleen, bloodwork, and breathing tests—are designed to manage your health proactively. By tailoring these tests to your specific diagnosis, your care team can catch complications early and adjust your treatment to keep you as healthy as possible [12][19].
Common questions in this guide
Why do I need routine tests for primary immunodeficiency if I feel well?
What long-term complications can primary immunodeficiency cause?
What tests monitor lung complications such as GLILD?
Can lung disease worsen even if my breathing tests are normal?
What symptoms should prompt me to contact my primary immunodeficiency care team?
Related questions
Show more
Get notified when new evidence is published on Primary immunodeficiency.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (19)
- 1
Unmasking inborn errors of immunity: identifying the red flags of immune dysregulation.
Cortesi M, Dotta L, Cattalini M, et al.
Frontiers in immunology 2024; (15()):1497921 doi:10.3389/fimmu.2024.1497921.
PMID: 39749336 - 2
Treatment and management of primary antibody deficiency: German interdisciplinary evidence-based consensus guideline.
Hanitsch L, Baumann U, Boztug K, et al.
European journal of immunology 2020; (50(10)):1432-1446 doi:10.1002/eji.202048713.
PMID: 32845010 - 3
Granulomatous-Lymphocytic Interstitial Lung Disease Mimicking Sarcoidosis.
Perlman DM, Sudheendra MT, Racilla E, et al.
Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG 2021; (38(3)):e2021025 doi:10.36141/svdld.v38i3.11114.
PMID: 34744421 - 4
The broad spectrum of lung diseases in primary antibody deficiencies.
Cinetto F, Scarpa R, Rattazzi M, Agostini C
European respiratory review : an official journal of the European Respiratory Society 2018; (27(149)) doi:10.1183/16000617.0019-2018.
PMID: 30158276 - 5
Interstitial lung disease in patients with common variable immunodeficiency disorders: several different pathologies?
Patel S, Anzilotti C, Lucas M, et al.
Clinical and experimental immunology 2019; (198(2)):212-223 doi:10.1111/cei.13343.
PMID: 31216049 - 6
Diagnostic testing for interstitial lung disease in common variable immunodeficiency: a systematic review.
Bintalib HM, van de Ven A, Jacob J, et al.
Frontiers in immunology 2023; (14()):1190235 doi:10.3389/fimmu.2023.1190235.
PMID: 37223103 - 7
Clinical practice guideline for the diagnosis of granulomatous-lymphocytic interstitial lung disease in patients with common variable immunodeficiency disorders: an ERS Clinical Research Collaboration.
Bintalib HM, van de Ven AAJM, Rojas-Reyes MX, et al.
The European respiratory journal 2026; (68(3)) doi:10.1183/13993003.02224-2025.
PMID: 42350065 - 8
Monitoring patients with uncomplicated common variable immunodeficiency: a systematic review.
Lee EY, Betschel S, Grunebaum E
Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology 2022; (18(1)):21 doi:10.1186/s13223-022-00661-7.
PMID: 35264237 - 9
Pulmonary surveillance in inborn errors of immunity: current challenges and emerging approaches.
Hoptioncann E, Eddy RL, Biggs CM, Rayment JH
Frontiers in immunology 2026; (17()):1797843 doi:10.3389/fimmu.2026.1797843.
PMID: 42245666 - 10
Lessons Learned From the Clinical Presentation of Common Variable Immunodeficiency Disorders: A Systematic Review and Meta-Analysis.
Janssen LMA, van der Flier M, de Vries E
Frontiers in immunology 2021; (12()):620709 doi:10.3389/fimmu.2021.620709.
PMID: 33833753 - 11
Cellular and molecular mechanisms breaking immune tolerance in inborn errors of immunity.
Sogkas G, Atschekzei F, Adriawan IR, et al.
Cellular & molecular immunology 2021; (18(5)):1122-1140 doi:10.1038/s41423-020-00626-z.
PMID: 33795850 - 12
Primary immunodeficiency diseases in lung disease: warning signs, diagnosis and management.
Soler-Palacín P, de Gracia J, González-Granado LI, et al.
Respiratory research 2018; (19(1)):219 doi:10.1186/s12931-018-0923-8.
PMID: 30419907 - 13
The Etiologic Landscape of Lymphoproliferation in Childhood: Proposal for a Diagnostic Approach Exploring from Infections to Inborn Errors of Immunity and Metabolic Diseases.
Costagliola G, De Marco E, Massei F, et al.
Therapeutics and clinical risk management 2024; (20()):261-274 doi:10.2147/TCRM.S462996.
PMID: 38770035 - 14
Inborn errors of immunity presenting with lymphoproliferation: lessons from a case series.
Costagliola G, De Marco E, Consonni F, et al.
Annals of hematology 2025; (104(6)):3117-3127 doi:10.1007/s00277-025-06456-1.
PMID: 40553169 - 15
Current clinical spectrum of common variable immunodeficiency in Spain: The multicentric nationwide GTEM-SEMI-CVID registry.
Cabañero-Navalon MD, Garcia-Bustos V, Nuñez-Beltran M, et al.
Frontiers in immunology 2022; (13()):1033666 doi:10.3389/fimmu.2022.1033666.
PMID: 36389743 - 16
Clinical and Immunologic Characteristics of Non-Hematologic Cancers in Patients with Inborn Errors of Immunity.
Delavari S, Wang Y, Moeini Shad T, et al.
Cancers 2023; (15(3)) doi:10.3390/cancers15030764.
PMID: 36765721 - 17
Inborn Errors of Immunity and Cancer.
Tiri A, Masetti R, Conti F, et al.
Biology 2021; (10(4)) doi:10.3390/biology10040313.
PMID: 33918597 - 18
Lymphoproliferation in Inborn Errors of Immunity: The Eye Does Not See What the Mind Does Not Know.
Sharma S, Pilania RK, Anjani G, et al.
Frontiers in immunology 2022; (13()):856601 doi:10.3389/fimmu.2022.856601.
PMID: 35603189 - 19
Pulmonary Manifestations of Inborn Errors of Immunity: Diagnostic and Therapeutic Insights.
Napiorkowska-Baran K, Cofta S, Treichel P, et al.
Life (Basel, Switzerland) 2025; (15(12)) doi:10.3390/life15121838.
PMID: 41465777
This page explains routine monitoring and possible long-term complications of primary immunodeficiency for informational purposes only; it does not constitute medical advice. Your immunology team should individualize your tests and tell you when new symptoms need prompt attention.